On a serious note, What Eire was trying to convey is that our IP is still ours and that what matters, the past have proven that no matter how good our products were (Lemaitre calls it next gen) it was hard to market it ourselves.
So lesson learned and moving forward, the strategy with TAVR is to find a partner and then continue with research and commercialization.
The more Lemaitre sells patches the more it proves and validates to potential tavr partners on how great our tissue is.
The future is looking very bright now that the company can concentrate on progressing further uses of the IP without the distractions of trying to sell, infusion and immune therapy.
Admedus 2.0 is in the making.
DYOR
Ann: CardioCel and VascuCel rights sold to LeMaitre Vascular, page-249
-
- There are more pages in this discussion • 41 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$9.91 |
Change
-0.090(0.90%) |
Mkt cap ! $209.4M | |||
| Open | High | Low | Value | Volume |
| $10.00 | $10.00 | $9.65 | $70.76K | 7.202K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300 | $9.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $9.91 | 475 | 2 |
View Market Depth
| Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
| AVR (ASX) Chart |